As of the latest Form 4 filed Jun 29, 2026.
What CVS Health Corp insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 42 most recent filings for CVS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-29 | 2026-06-26 | Clark James David SVP, Cont & Chief Acct Officer | FTax | −454.00 | $90.98 | $41.3K | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-31 | Newman Brian EVP, Chief Financial Officer | FTax | −2.48K | $90.98 | $225K | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-31 | Compton-Phillips Amy EVP, Chief Medical Officer | FTax | −7.62K | $90.98 | $693K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-21 | AGUIRRE FERNANDO Director | DDisposition | −1.56K | $93.50 | $146K | No | Form 4 ↗ |
| 2026-05-22 | 2026-05-20 | AGUIRRE FERNANDO, Director | DDisposition | −30.4K | $93.78 | $2.85M | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-21 | ROBBINS LARRY Director | SSale | −370K | $93.45 | $34.6M | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-20 | ROBBINS LARRY, Director | SSale | −800.00 | $96.28 | $77.0K | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-20 | ROBBINS LARRY, Director | SSale | −66.9K | $95.67 | $6.40M | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-20 | ROBBINS LARRY, Director | SSale | −153K | $94.81 | $14.5M | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-20 | ROBBINS LARRY, Director | SSale | −798K | $93.48 | $74.6M | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | ROBBINS LARRY, Director | SSale | −151.00 | $95.18 | $14.4K | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | ROBBINS LARRY, Director | SSale | −1.98M | $94.45 | $187M | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | AGUIRRE FERNANDO Director | AAward | +1.56K | $97.15 | $152K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Balser Jeffrey R. Director | AAward | +2.06K | $97.15 | $200K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | KIRBY J SCOTT Director | AAward | +1.45K | $97.15 | $141K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Norwalk Leslie V Director | AAward | +1.45K | $97.15 | $141K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | SANSONE GUY P Director | AAward | +1.45K | $97.15 | $141K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | BROWN C DAVID II Director | AAward | +1.54K | $97.15 | $150K | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | Mandadi Tilak EVP, Chief Exp & Tech Officer | SSale | −69.6K | $89.58 | $6.23M | No | Form 4 ↗ |
| 2026-04-02 | 2026-04-01 | Shah Prem S EVP and Group President | FTax | −1.48K | $72.49 | $108K | No | Form 4 ↗ |
| 2026-04-02 | 2026-04-01 | Nelson Steven H EVP and President, Aetna | FTax | −2.43K | $72.49 | $176K | No | Form 4 ↗ |
| 2026-04-02 | 2026-04-01 | Mandadi Tilak EVP, Chief Exp & Tech Officer | FTax | −3.63K | $72.49 | $263K | No | Form 4 ↗ |
| 2026-04-02 | 2026-04-01 | Khichi Samrat S. EVP, CPO and General Counsel | FTax | −3.54K | $72.49 | $257K | No | Form 4 ↗ |
| 2026-04-02 | 2026-04-01 | Joyner J. David President, CEO and Chair | FTax | −8.03K | $72.49 | $582K | No | Form 4 ↗ |
| 2026-04-02 | 2026-04-01 | Clark James David SVP, Cont & Chief Acct Officer | FTax | −3.26K | $72.49 | $236K | No | Form 4 ↗ |
| 2026-04-02 | 2026-04-01 | CAPOZZI HEIDI B EVP and Chief People Officer | FTax | −1.33K | $72.49 | $96.7K | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Shah Prem S EVP and Group President | AAward | +25.1K | $71.82 | $1.80M | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Newman Brian EVP, Chief Financial Officer | AAward | +19.5K | $71.82 | $1.40M | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Nelson Steven H EVP and President, Aetna | AAward | +22.3K | $71.82 | $1.60M | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Mandadi Tilak EVP, Chief Exp & Tech Officer | AAward | +22.3K | $71.82 | $1.60M | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Khichi Samrat S. EVP, CPO and General Counsel | AAward | +12.5K | $71.82 | $900K | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Joyner J. David President, CEO and Chair | AAward | +86.3K | $71.82 | $6.20M | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Compton-Phillips Amy EVP, Chief Medical Officer | AAward | +5.57K | $71.82 | $400K | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Clark James David SVP, Cont & Chief Acct Officer | AAward | +11.1K | $71.82 | $800K | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | CAPOZZI HEIDI B EVP and Chief People Officer | AAward | +10.0K | $71.82 | $720K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-19 | Gallina John E Director | AAward | +582.00 | $71.86 | $41.8K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Khichi Samrat S. EVP, CPO and General Counsel | FTax | −7.89K | $79.60 | $628K | No | Form 4 ↗ |
| 2026-03-02 | 2026-02-28 | Joyner J. David President and CEO | FTax | −1.94K | $79.90 | $155K | No | Form 4 ↗ |
| 2026-01-27 | 2025-01-23 | Nelson Steven H EVP and President, Aetna | PPurchase | +24.00 | $53.70 | $1.29K | No | Form 4 ↗ |
| 2026-01-05 | 2026-01-01 | Shah Prem S EVP and Group President | FTax | −247.00 | $80.13 | $19.8K | No | Form 4 ↗ |
| 2024-05-02 | 2024-05-02 | LUDWIG EDWARD J Director | PPurchase | +1.00K | $53.88 | $53.9K | No | Form 4 ↗ |
| 2024-05-02 | 2024-05-02 | Mahoney Michael F Director | PPurchase | +9.18K | $54.49 | $500K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also CVS’s full analysis or the market-wide insider trading feed. The tabs above jump to CVS’s other SEC data.
Source: SEC Form 4 filings for CVS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.